Pharmaceutical companies need to patient and financial value through the development and commercialisation of products. This requires a clear strategy with robust product planning, execution and tracking. The purpose of this presentation is to describe the key elements that need to be considered in order to optimise product strategy and planning.
Excellence in product strategy and planning Read More »
Regulatory Affairs organisations interface with many internal and external stakeholders and will need to continue to respond to a dynamic and evolving environment. We outline 5 priorities that Regulatory Affairs organisations must explore in order to prepare for the future: Enhance the Regulatory Affairs and Pharmacovigilance interface Optimise outsourcing Prepare for new modalities Drive efficiencies and quality through automation Explore machine learning
The future of regulatory affairs Read More »
We are thrilled to announce that the Lucid Group has just received our Silver Award Ecovadis Certification in our first ever group wide submission, after receiving a Bronze Award for DiD in the US last year. Ecovadis is the international sustainability standard and is the world’s largest and most trusted provider of business sustainability ratings.
Lucid Group receives EcoVadis certification Read More »
On Friday 28 July, nine colleagues from our Rubix team headed to the Peak District to volunteer their time and help care for its precious wild landscape. This was as part of our Lucid Spirit programme, an initiative set up to give back to communities and the environment. The team were guided by Rob Kenning
Lucid Spirit programme Read More »
Technological developments and the ever increasing breadth and depth of new information and evidence being generated have driven many life sciences companies to focus on making information accessible to external stakeholders across multiple channels in a seamless way – often referred to as ‘omnichannel strategy’. However, there is often too much focus on technology and not on the strategic
Optimising external engagement in the digital age Read More »
The UN Global Compact is the world’s largest corporate sustainability initiative that invites companies to align their culture, strategies and operations with universal principles on human rights, labour, environment and anti-corruption and take actions that advance societal goals. The attached letter (link to supplied file UN_Compact_Letter.pdf): from Sanda Ojiambo (Executive Director United Nations Global Compact) to our
Lucid Group is officially a member of the United Nations Global Compact Read More »
As life science brands initiate sophisticated digital omnichannel marketing efforts, or build on those beginnings, a lot of the focus has been on connecting various channels in order to create a more seamless brand experience. However, to create more meaningful brand experiences, brand strategies and communications need to align with existing HCPs behaviors more closely
At Lucid, we pride ourselves not on just understanding science, but also understanding the clinical environment and implications. . Here’s our latest insight report, focused on IBD from Digestive Disease Week in Chicago, created in collaboration with the wonderful Jennie Clough and Joshua McGuire. #lucidlife #clinicalinsight #ddwsummary .
Clinical insights and implications from DDW Read More »
Do doctors’ personalities change because of the specialty they chose to practice…or do they choose their specialty based on their underlying personality traits? This was a hot topic when I was in medical school. We wondered, for example, if future pediatricians were more nurturing and caring by nature and if aspiring surgeons were just “born
You are what you treat: Medical specialty choices, personalities, and perspectives Read More »
Decentralised Clinical Trials (DCTs) present a biopharmaceutical company with a series of opportunities and challenges. We highlight the challenges and examine the value the individual DCT elements may create for patients, investigators and site staff, regulators and ethics committees, and the sponsor. We also contend that for a DCT to be truly patient-centric, the patient must be provided with
Decentralised clinical trials: Achieving our ambition? Read More »
